Organovo Holdings (FRA:4OR1) 3-Year EBITDA Growth Rate : 13.90% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings 3-Year EBITDA Growth Rate?

Organovo Holdings's EBITDA per Share for the three months ended in Dec. 2023 was €-0.36.

During the past 3 years, the average EBITDA Per Share Growth Rate was 13.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 24.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 19.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Organovo Holdings was 34.10% per year. The lowest was -508.50% per year. And the median was 18.40% per year.

Competitive Comparison of Organovo Holdings's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Organovo Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organovo Holdings's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's 3-Year EBITDA Growth Rate falls into.

Organovo Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Organovo Holdings (FRA:4OR1) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Organovo Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Organovo Holdings (FRA:4OR1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (FRA:4OR1) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ONVO:USA 4OR1:Germany

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Organovo Holdings (FRA:4OR1) Headlines

No Headlines